canakinumab

Ligand id: 6773

Name: canakinumab

Immunopharmacology Comments
Canakinumab is being evaluated as an anti-inflammatory therapy for atherosclerosis [3] (for example see Phase 3 clinical trial NCT01327846).
Immunopharmacology Disease
Disease X-Refs Comment References
Muckle-Wells syndrome OMIM: 191900
Orphanet: ORPHA575
An anti-IL-1β therapeutic approved for Muckle-Wells syndrome.
Familial cold autoinflammatory syndrome 1; FCAS1 OMIM: 120100
Orphanet: ORPHA47045
An anti-IL-1β therapeutic approved for FCAS1.
Juvenile idiopathic arthritis- systemic OMIM: 604302
An anti-IL-1β therapeutic approved for sJIA.